Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761888 | 0.86 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTL3MBTL1TP53 | |
| SCHEMBL28429406 | 0.77 | TP53 (0.59) | ALDH1A1LMNAMAPTTP53CNR1 | |
| SCHEMBL5368616 | 0.77 | ALDH1A1 (0.56) | ALDH1A1LMNAL3MBTL1KMT2AGAA | |
| SCHEMBL5365137 | 0.76 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTL3MBTL1KMT2A | |
| SCHEMBL5762315 | 0.75 | PAX8 (0.45) | ALDH1A1LMNAMAPTTP53KMT2A | |
| SCHEMBL14578750 | 0.73 | LMNA (0.61) | ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL5359176 | 0.72 | MEN1 (0.55) | ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL5370611 | 0.71 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTL3MBTL1KMT2A | |
| SCHEMBL5760505 | 0.70 | ALDH1A1 (0.54) | ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL15164347 | 0.69 | F2RL1 (0.62) | ALDH1A1LMNAMAPTL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556371-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | WINSTON PHARMACEUTICALS LLC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | GARST MICHAEL (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | GARST MICHAEL (US) | 2005-06-30 | — | — | US | disclosed |
| US-6897227-B2 | Prodrugs of proton pump inhibitors | Winston Pharmaceuticals, Inc. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | ALDH1A1 397/4885LMNA 4395/4885MAPT 4100/4885 |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | ABCB11, SLC10A2, SI | ALDH1A1 405/4885LMNA 4347/4885MAPT 4128/4885 |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | ALDH1A1 494/4885LMNA 4415/4885MAPT 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.